Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients

Breast Cancer Research and Treatment

Volumn 113, Issue 2, 2009, Pages 321-326

  Markovitch, O ^a   Tepper, R ^a   Fishman, A ^a   Aviram, R ^a   Cohen, I ^a  

^a MEIR MEDICAL CENTER   (Israel)

Author keywords

Aromatase inhibitors; Endometrial thickness; Tamoxifen; Ultrasound

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL FEATURE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIUM; ENDOMETRIUM ATROPHY; ENDOMETRIUM POLYP; FEMALE; HUMAN; HYSTEROSCOPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MEASUREMENT; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; THICKNESS; TRANSVAGINAL ECHOGRAPHY; TREATMENT DURATION;

AGED; ANTHROPOMETRY; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; ENDOMETRIUM; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; REPRODUCTIVE HISTORY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TIME FACTORS;

EID: 58149235054     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-9941-4     Document Type: Article

References (21)

1. E Lahti G Blanco A Kauppila 1993 Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen Obstet Gynecol 81 660 664
2. I Cohen DJD Rosen J Shapira 1994 Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients Gynecol Oncol 52 185 190
3. S Cecchini S Ciatto R Bonardi 1996 Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients with tamoxifen treatment Gynecol Oncol 60 409 411
4. B Gerber A Krause H Muller 2000 Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound J Clin Oncol 18 3464 3470
5. I Cohen R Azaria J Shapira Y Dror R Tepper 2002 Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women Cancer 94 3101 3106
6. The ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists' Group 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial Lancet 359 2131 2139
7. P Goss J Ingle S Martino 2003 A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 1 10
8. S Duffy TL Jackson M Lansdown 2006 The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment Human Reprod 21 545 553
9. Garrone O, Mezi S, Occelli M et al (2003) Reversal of tamoxifen induced endometrial modifications by switching to letrozole in early breast cancer patients: a prospective transvaginal ultrasound study (TVUS). Proc Am Soc Clin Oncol 22:69
10. L Morales D Timmerman P Neven 2005 Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients Ann Oncol 16 70 74
11. G Garuti F Cellani G Centinaio G Montanari G Nalli M Luerti 2006 Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors Gynecol Oncol 103 599 603
12. O Markovitch R Tepper A Fishman R Aviram I Cohen 2007 Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients Breast Cancer Res Treat 101 185 190
13. B Gerber A Krause T Reimer 2006 Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen- induced endometrial pathology Clin Cancer Res 12 1245 1250
14. CDB Love BB Muir JB Scrimgeour RCF Leonard P Dillon JM Dixon 1999 Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening J Clin Oncol 17 2050 2054
15. A Decensi V Fontana S Bruno C Gustavino B Gotteschi A Casta 1996 Effect of tamoxifen on endometrial proliferation J Clin Oncol 14 434 440
16. Berliere M, Galant C, Charles A et al (2002) Endometrial evaluation is a very important tool in the management of breast cancer patients. Eur J Cancer (Suppl) 6: S67-S68
17. I Cohen Y Beyth R Azaria 2000 Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients Brit J Obstet Gynecol 107 1083 1087
18. MV Menada A Papadia P Lorenzi 2004 Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients Eur J Gynaec Oncol 25 321 323
19. F Boccardo A Rubagotti M Puntoni 2005 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial J Clin Oncol 23 5238 5247
20. T Hachisuga T Saito J Kigawa 2004 Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for breast cancers Gynecol Oncol 95 139 144
21. SE Ferguson RA Solow A Amsterdam 2005 Comparison of uterine malignancies that develop during and following tamoxifen therapy Gynecol Oncol 101 322 326